trade and other payables of THB 207 million, and a decline in liabilities classified as held for sale (THB 394 million) post-divestment of Future Group. As of 31 December 2018, the Company had total
Company. The Granting of Loan Transaction is classified as a Class 5 Connected Transaction, i.e., an offer of financial assistance, pursuant to the Notification of the Capital Market Supervisory Board No
institutional investor that have to classified as the liabilities amounting to THB 1,004.92 million. Moreover, due to the fact that convertible debentures issued, the Company has sufficient capital and can repaid
Administration (CFDA) at the beginning of 2 0 1 8 as the Company had to redesign its packaging to comply with the requirements of the license. Furthermore, the Company also found it necessary to adjust its sales
year to be in parallel with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for
ongoing outbreak of COVID–19, forcing many customers to adjust their working method which have an effect on the operation and delivery of the Company's projects that cause the operation to be delayed than
with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for certain expenses that the
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
that the Company managed to properly slash sales expenses from the previous year to be in parallel with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and